A5007692759- Cancer-related Molecular Pathways
- Microtubule and mitosis dynamics
- Neuroblastoma Research and Treatments
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Immune Response and Inflammation
- CAR-T cell therapy research
- interferon and immune responses
- Pancreatic and Hepatic Oncology Research
- Skin Diseases and Diabetes
- Immune cells in cancer
- Endometrial and Cervical Cancer Treatments
- Urologic and reproductive health conditions
- Virus-based gene therapy research
- Parasitic Diseases Research and Treatment
- Epigenetics and DNA Methylation
- Autoimmune and Inflammatory Disorders
- Fibroblast Growth Factor Research
- RNA Interference and Gene Delivery
- Cancer Research and Treatments
- Ocular Oncology and Treatments
- Parasites and Host Interactions
- Inflammatory Biomarkers in Disease Prognosis
The University of Texas MD Anderson Cancer Center
2021-2025
Austin College
2025
The University of Texas at Austin
2025
The University of Texas Health Science Center at Houston
2022-2024
Tumor microbiota can produce active metabolites that affect cancer and immune cell signaling, metabolism, proliferation. Here, we explore tumor gut microbiome features chemoradiation response in patients with cervical using a combined approach of deep sequencing, targeted bacterial culture, vitro assays. We identify an obligate L-lactate-producing lactic acid bacterium found tumors, Lactobacillus iners, is associated decreased survival patients, induces chemotherapy radiation resistance...
Human papillomavirus (HPV)-driven cancers include head and neck squamous cell carcinoma cervical cancer represent approximately 5% of all cases worldwide. Standard-of-care chemotherapy, radiotherapy, immune checkpoint inhibitors (ICIs) are associated with adverse effects limited responses in patients HPV-driven cancers. The integration targeted therapies ICIs may improve outcomes. In a previous study, we demonstrated that Aurora kinase A (AURKA, A) lead to apoptosis human HPV-positive cells...
<p>Supplementary Figure S4. Gating strategy for flow cytometry analysis of PBMC.</p>
<p>Supplementary Figure S3. Kaplan-Meier curves for progression-free survival (PFS) and overall (OS) in phase 2 patients, stratified by PD-L1 CPS score.</p>
<p>Supplementary Figure S8. Changes in absolute lymphocyte count (ALC) from baseline to 6 weeks of therapy.</p>
<p>Supplementary Figure S7. Flow cytometry analyses of circulating lymphocyte subsets in patients with acquired resistance (AR, <i>n</i>=8) or <i>de novo</i> (DR, n=4) to prior anti-PD1 immunotherapy.</p>
<p>Supplementary Figure S5. Flow cytometric analysis of PBMCs isolated from blood samples collected at baseline the patients with PD or SD.</p>
<p>Supplementary Figure S6. Plasma samples collected at the baseline from participants of trial were compared between PD and SD groups patients by Luminex analyses to profile various cytokines chemokines.</p>
<p>Supplementary Figure S2. Baseline and follow-up neck CT scans of a patient with recurrent metastatic squamous cell carcinoma.</p>
<p>Supplementary Figure S9. Plasma concentrations of alisertib on Cycle 1 Day (C1D1) and 7 (C1D7).</p>
<p>Supplemental Methods S1</p>
<div>AbstractPurpose:<p>Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy immunotherapy a considerable need. Aurora kinase A inhibition leads apoptosis immunogenic death in preclinical models of human papilloma virus (HPV)–driven cancers.</p>Patients Methods:<p>Alisertib was administered orally twice daily on days 1–7 pembrolizumab day 1 21-day cycle adults with advanced solid tumors (phase I) or...
<p>Supplementary Figure S1. Survival curves for phase 1 study patients based on Kaplan-Meier analysis.</p>
The immune system's role in mediating the cytotoxic effects of chemoradiotherapy remains not completely understood. integration immunotherapies into treatment will require insight features and timing microenvironment associated with response. Here, we investigated circulating neutrophils tumor-associated myeloid cells (TSAMs) as potential agents biomarkers for disease-related outcomes locally advanced cervical cancer (LACC).Hematologic parameters two LACC patient cohorts, a retrospective...
Trichuriasis is one of the most common neglected tropical diseases world’s poorest people. A recombinant vaccine composed Tm- WAP49, an immunodominant antigen secreted by adult Trichuris stichocytes into mucosa cecum to which parasite attaches, under development. The prototype being evaluated in a mouse model muris infection, with ultimate goal producing mucosal through intranasal delivery. Intranasal immunization mice WAP49 formulated adjuvant OCH, truncated analog alpha-GalCer...
High-risk human papillomaviruses (HPVs) are associated with genital and oral cancers, the incidence of HPV+ head neck squamous cell cancers is fast increasing in USA worldwide. Survival rates for patients locally advanced disease poor after standard-of-care chemoradiation treatment. Identifying antitumor host immune mediators important treatment response designing strategies to promote them essential. We reported earlier that a syngeneic immunocompetent preclinical HPV tumor mouse model,...
Abstract High-risk type human papillomaviruses (HPV) are associated with genital and oral cancers, the incidence of head neck squamous cell cancers is fast increasing in USA worldwide. Survival rates for patients locally advanced disease poor variable after standard care (SOC) chemoradiation treatment (CRT). Identifying antitumor host immune mediators important response designing strategies to promote them essential improving clinical outcome. Antitumor immunity comprises adaptive innate...
Abstract Purpose: Effective therapy for recurrent head and neck squamous cell carcinoma (HNSCC) that is refractory to chemotherapy immunotherapy a considerable need. Aurora kinase A inhibition leads apoptosis immunogenic death in preclinical models of human papilloma virus (HPV)-driven cancers. Experimental Design: Alisertib was administered orally twice daily on days 1-7 pembrolizumab day 1 21-day cycle adults with advanced solid tumors (phase 1) or immunotherapy- platinum-resistant,...
<h3>Background</h3> Human Papillomavirus (HPV) cancers are uniquely antigenic with a ubiquitous and essential expression of the viral proteins E6 E7. Radiation therapy is in treating locally advanced HPV-associated cancers, including cervical cancers. (RT) may synergize immunotherapy to stimulate T-cell mediated anti-tumor affects by increasing flux tumors promoting pathways that result increased antigen presentation. To evaluate this, we conducting single-arm phase II trial combining...